Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • Contact

i2E Inc. leads $850,000 investment in Oklahoma-based Kirrhos Pharmaceuticals

By sarah | Featured, News | 0 comment | 12 September, 2019 | 0

September 12, 2019

Contact: Sarah Seagraves,
Senior VP for Marketing
(405) 813-2403
sseagraves@i2E.org

Oklahoma-based Kirrhos Pharmaceuticals is developing a novel, first-in-class treatment
for a severe form of non-alcoholic fatty liver disease known as NASH

OKLAHOMA CITY — i2E, Inc., recently led an $850,000 seed investment in Oklahoma
City-based Kirrhos Pharmaceuticals, which is developing a therapeutic for NASH, a life-
threatening liver condition that afflicts up to 12 percent of adult Americans.

NASH — nonalcoholic steatohepatitis – is associated with a spectrum of diseases
centered around the liver, said David Martin, PharmD, Kirrhos Pharmaceuticals chief
executive officer. It is termed a “modern lifestyle disease” by the NASH Education
Program, a collaborative initiative by stakeholders in NASH research and treatment.

“It’s basically a lifestyle disease, brought on primarily by a high-fat diet,” Martin said.
“People that are at high risk for it are people who are overweight, may or may not have
diabetes or are prone to diabetes and have a generally poor diet.”

The investment into Kirrhos Pharmaceuticals includes $425,000 from the i2E-managed
Oklahoma Accelerate Fund, along with matching investment from Angel investors.

The seed investment will allow Kirrhos to conduct preclinical proof-of-concept research
into its therapeutic, Martin said. A successful proof-of-concept would lead to a larger
Series A investment round that could carry to company into clinical trials, he said.

“NASH is a debilitating and potentially fatal disease with no approved therapeutic
treatment on the market,” said Carol Curtis, Ph.D., i2E Management Company vice
president and director of investments. “If Kirrhos is successful, it will bring relief to
millions of patients in the U.S. and worldwide.”

Kirrhos is the first spinout from Oklahoma City-based Ascend BioVentures, a
pharmaceutical accelerator formed in 2018 as a subsidiary of i2E in partnership with the
University of Oklahoma, the Oklahoma Medical Research Foundation (OMRF) and the
Presbyterian Health Foundation.

The Oklahoma Seed Capital Fund is a state-appropriated investment fund managed by
i2E through the Oklahoma Center for the Advancement of Science and Technology.

About Kirrhos Pharmaceuticals
Founded in early 2019, Kirrhos Pharmaceuticals is advancing a novel, “first-in-class”
therapeutic to treat a progressive non-alcoholic fatty liver disease known as NASH. Built
upon a platform technology licensed from a California-based research company, Kirrhos
anticipates future development of treatments for other fibrotic disease indications such
pulmonary fibrosis, kidney fibrosis and potentially cancer.

About i2E, Inc.
With offices in Oklahoma City and Tulsa, OK, i2E’s nationally recognized services
include business expertise and funding for Oklahoma’s emerging small businesses. i2E
has more than $60 million of investment capital under management. www.i2E.org

angel investors, Carol Curtis, Dave Martin, Kirrhos Pharmaceuticals, Oklahoma Seed Capital Fund

Related Post

  • State embraces collaborative culture with Oklahoma Innovation Model

    By sarah | Comments are Closed

    By Scott Meacham We are in difficult times — and when times are difficult, individuals, business, and even entire states have to do things differently. Think back to what was happening in Oklahoma in theRead more

  • Putting the disruption of 2020 to work

    By sarah | Comments are Closed

    By Scott Meacham Happy New Year! I don’t know if I have ever been so happy to end one year and begin the next. Times remain challenging, but in just the last few weeks, weRead more

  • Expand your network to add diversity to investment deal flow

    By sarah | 0 comment

    By Scott Meacham Companies that are more diverse produce better financial results — much better, according to the most recent report in the McKinsey & Company series “Delivering through Diversity.” In the McKinsey report, companiesRead more

  • Love’s Entrepreneur’s Cup overcomes pandemic to conduct virtual competition, honor winners in online ceremony

    By sarah | 0 comment

    Contact: Sarah Seagraves, Senior VP for Marketing (405) 813-2403 sseagraves@i2E.org May 1, 2020 OKLAHOMA CITY — Student entrepreneurs from college campuses across Oklahoma pitched winning business plans online to virtual panels of judges in theRead more

  • i2E leads $11.5 million investment in Oklahoma City-based Linear Health Sciences

    By sarah | 0 comment

    April 1, 2020 Contact: Sarah Seagraves, Senior VP for Marketing (405) 813-2403 sseagraves@i2E.org Oklahoma City, OK-based Linear Health Sciences has developed a globally patented medical device known as the Orchid Safety Release Valve (SRV), designedRead more

Leave a Comment

Cancel reply

You must be logged in to post a comment.

i2E-300dpi-Trans-Light
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
PHONE 405/235-2305
Click HERE for printable map with directions.

Tulsa Office

618 E. Third Street, Suite 1
Tulsa, OK 74120
PHONE 918/582-5592
Click HERE for printable map with directions.
Copyright 2021 i2E, Inc. | All Rights Reserved
  • #withOklahomaStartups
  • #withOklahomaStartups
  • #withOklahomaStartups- copy
  • 2016 BrewFest
  • 2018 Paulsen Award Application
  • 2019 Business Plan Submittal Form
  • 2019 Intent to Compete
  • 2019 Oral Competition Submittal Form
  • 2019 Paulsen Award Application
  • 2020 Business Plan Submittal Form
  • 2020 Oral Competition Submittal Form
  • 2020 Paulsen Award Application
  • 2021 Official Application Form
  • 2021 Oral Competition Submittal Form
  • 2021 Paulsen Award Application
  • 4DSales
  • About
  • About i2E
  • About Us
  • ACT Tulsa
  • Add Listing
  • Alkami
  • Biolytx
  • BP Endo
  • Clear River Enviro
  • Concept Fund
  • Contact
  • COVID-19 News from i2E
  • COVID19 Resources for Scalable Startups
  • CreditPoint
  • Datebox
  • DermaMedics
  • DEX Pump
  • DigitalSix
  • Directory
  • Directory Dashboard
  • Docvia
  • Driven Analytics
  • e3
  • e3 Goes Virtual
  • e3: #withOklahomaStartups
  • Entrepreneurial Development
  • Entrepreneurial Summit
  • Entrepreneurial Summit Speakers
  • Entrepreneurs-in-Residence
  • Entrepreneurship
  • Events
  • Events
  • Exaptive
  • Exerbotics
  • Expert TA
  • Founder’s Book Nook
  • Home
  • Home
  • i2E Directory
  • i2E Events
  • iMCI
  • iMCI Investment Funds
  • Investments
  • iRecommend
  • Kirrhos
  • Letter from iMCI’s Executive in Residence in a time of great uncertainty
  • Library
  • Lifetone
  • Linear Health Sciences
  • Love’s Cup
    • Forms
    • High Growth
    • Paulsen Awards
    • Small Business
    • Timeline
  • Love’s Cup is Unstoppable
  • Love’s Cup W-9
  • MaxQ
  • Moleculera Labs
  • Monscierge
  • MS Pen Technologies
  • My Account
  • News
  • Newsletter
  • Newsletter Archive
  • OKBio
  • OKBio Directory
  • OMRF Glioblastoma
  • Otologics Pharmaceuticals
  • Past Winners
  • PhotoniCare
  • PolySkope Labs
  • Portfolio
  • Portfolio 3
  • Private Partners Opportunity Fund
  • Progentec Diagnostics
  • Q&A with Kevin Moore
  • Q&A with Michael Basch
  • Quarterly Report
  • Raw Space for Rent
  • Resources
  • Roll to Roll Technologies
  • Selexys Pharmaceuticals
  • Send a Ride
  • Simergent
  • Spiers New Technologies
  • Synercon Technologies
  • Tailwind
  • Ten Nine Technologies
  • Testimonials
  • Tetherex Pharmaceuticals
  • The Greg Main Distinguished Scholar Award
  • THG Energy Solutions
  • Thoughts from local business leaders and startup founders on the effects of COVID on their industry
  • Thoughts Post Shut In
  • Tulsa Collab: COVID-19 Efforts & Resources for Entrepreneurs
  • Tulsa GEW
  • Valve Systems International
  • Venture Advisory Services
  • Video
  • Virtuoso
  • Webmail Test Page
  • WeGoLook
  • Well Checked Systems
  • Whiteboard CRM
i2E